MiniMed aims to develop fully automated insulin pumps comparable to self-driving cars, CEO Que Dallara announced at the Consello Spark Summit following the company's recent IPO.
MiniMed is pursuing automation in diabetes management as it enters the public markets. The company's goal is to create insulin delivery systems that require minimal user intervention, similar to autonomous vehicle technology.
CEO Dallara's statement positions MiniMed as an innovator in medical device automation. The self-driving car analogy suggests the company is working toward pumps that automatically adjust insulin delivery based on continuous glucose monitoring and predictive algorithms.
Automated insulin delivery systems, sometimes called artificial pancreas technology, represent a significant advancement in diabetes care. These devices can reduce the burden of manual glucose monitoring and insulin dosing for patients.
The company's post-IPO focus on automation reflects broader industry trends toward connected health devices and AI-driven medical technology. MiniMed joins competitors like Medtronic in advancing closed-loop insulin delivery systems.
The timeline and specific technological milestones for MiniMed's autonomous pump development remain undisclosed.
Town, an enterprise personal AI assistant platform, is in talks to raise funding at a $1 billion valuation in a round led by Index Ventures, according to sources.
Product management platform Linear reached $100M in annual recurring revenue and conducted a $99M employee tender offer at a $2.5B valuation, doubling its valuation from $1.25B in 2025.
Flipboard is acquiring Bluesky feed-building startup Graze, integrating its ad technology and creator monetization tools into its open social web platform.
Artificial intelligence is fundamentally changing how startups operate, not just what they build. According to Floodgate co-founder Ann Miura-Ko, companies are deploying AI agents across engineering, sales, marketing, and strategy to accelerate learning and execution.